Real-World use of clotting factor in iraqi haemophilia patients examined
NCT ID NCT06574984
First seen Nov 01, 2025 · Last updated Jun 23, 2026 · Updated 26 times
Summary
This completed study observed how 329 Iraqi male patients with haemophilia A used turoctocog alfa (a clotting factor) in their daily care. Researchers reviewed medical records to see how the drug was given and how many bleeding episodes occurred. The goal was to describe real-world treatment patterns, not to change how patients were treated.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HAEMOPHILIA A are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Basrah Haemoplhilia centre
Basra, 61001, Iraq
-
Hilla Haemophilia centre
Hillah, 51001, Iraq
-
Karbala Haemophilia centre
Karbala, 56001, Iraq
-
Kirkuk Centre for Cancer and Blood Disorders
Kirkuk, 36001, Iraq
-
Najaf Haemophilia Centre
Najaf, 54001, Iraq
-
National centre for Hamophilia
Baghdad, 10001, Iraq
-
Novo Nordisk Investigational Site
Baghdad, Iraq
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
turoctocog alfa (a clotting factor VIII replacement therapy)
What this could lead to
If successful, this study could help doctors understand how turoctocog alfa is used in real-world settings and guide better management of haemophilia A.
What could go wrong
This is an observational study that only looks back at existing records, so it cannot prove cause and effect. Results may not apply to other populations or settings.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.